Ibalizumab is likely to be approved in November if delays can be avoided. It is administered by IV every two weeks and will be the first long acting HIV drug on the market.
PRO 140 could be the second one but it is still more than a year away from approval.
I have not focused on others but know there are several in the testing phase. I don't think any has advanced to phase III yet but that is not based on an exhaustive review of the landscape, just what I believe I read somewhere in the last months.
The ones that are being studied are mostly once a month drugs. The second version of Ibalizumab, which has a long way to go before getting on the market, is targeting a once a month injection.
News 
Market Data 
Discover 
AI
